Finished product reference
Maprotiline Hydrochloride
Tablet · Oral · 75 mg
- List code
- 784
- Pharmacologic class
- Tetracyclic antidepressant
What it is and how it works
Maprotiline is a tetracyclic antidepressant that potently and selectively inhibits noradrenaline reuptake at presynaptic nerve terminals, with little effect on serotonin reuptake. It also has antihistaminic and moderate antimuscarinic and alpha-adrenoceptor blocking properties, contributing to sedation and adverse effects.
Indications
Depressive illness, particularly where sedation is required.
Dosage and administration (summary)
Adults: initially 25–75 mg daily orally in divided doses or as a single dose at night, adjusted according to response, usually to a maximum of 150 mg daily; lower doses in the elderly.
Contraindications
Recent myocardial infarction, heart block or arrhythmias; history of epilepsy or lowered seizure threshold; use with or within 14 days of an MAO inhibitor; mania; severe liver disease; angle-closure glaucoma and urinary retention.
Warnings and precautions
Risk of seizures is dose-related and higher than with many tricyclic antidepressants; avoid rapid dose escalation and high doses. Increased risk of suicidal thoughts and behaviour, especially in young adults, at the start of treatment. Antimuscarinic effects, orthostatic hypotension, QT prolongation and sedation may occur; caution in cardiovascular disease, prostatic hypertrophy and in the elderly; dangerous in overdose.
Pregnancy
Use only if clearly needed; neonatal withdrawal effects may occur after use in late pregnancy.
Storage and supply
Store below 25–30 °C, protected from moisture.
Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.
Other presentations of the same active ingredient
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.